HQH News and Press, Tekla Healthcare Investors From 11/15/19

Note: This article was released to members on October 19, 2019. Chemist's Closed-End Fund Report Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end funds [CEFs] for further due diligence and investigation. Previous editions of ...

Photo Source: REUTERS/Yuri Gripas. China's Vice Premier Liu He looks on during a meeting with U.S. President Donald Trump in the Oval Office of the White House in Washington, U.S., October 11, 2019. For the month, 61% of all closed-end funds (BATS: CEFS ) posted net-asset-value ((NAV))-b...

Usually, many people associate closed-end funds with high risk, high fees, and high leverage. Some would argue that they have no place in a conservative or retirement portfolio. We tend to differ. We believe that in spite of their obvious risks if used the right way, they can provide high-in...

President Trump signed an executive order that he says will make "Medicare even better and we're not letting anyone -- it will never be taken away from you," he told an audience at an event at a Florida retirement community. More news on: Health Care Select Sect SPDR ETF, Vanguard Health...

"Don't confuse brains with a bull market" This quote attributed to Humphrey B. Neill reminds me that the primary driver of the portfolio's growth has been our long bull market. The fifth edition of Neill's book, The Art of Contrary Thinking , is available via a free PDF download. From page ...

For income investors, closed-end funds, or CEFs, are an attractive investment class that offers high income generally in the range of 6%-10%, broad diversification in terms of a variety of asset classes, and market matching total returns in the long term if selected carefully. However, CEF...

One of the healthcare closed-end funds that I have been covering on this site over the past year or two is Tekla Healthcare Investors ( HQH ). This is also a fund that deserves special consideration in today's market due to its rather impressive performance in the face of the market volatility...

In spite of the high volatility and the wild ride in 2019, the markets are only about 6% below their new all-time high achieved back in July. In fact, it's already the longest bull market in history. Still, there are plenty of risks on the horizon. Trade wars on multiple fronts are keeping t...

By Stephen H. Dover, CFA, Executive Vice President, Head of Equities, Krzysztof Musialik, CFA, Research Analyst, Franklin Templeton Emerging Markets Equity, and Steve Kornfeld, CFA, Portfolio Manager, Research Analyst, Franklin Equity Group The biopharma industry has the potential to save...

By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...